- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00842686
Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study (CRAB)
The use of preoperative chemoradiation and adjuvant chemotherapy with 5-FU based chemotherapy reduced local recurrence rate to less than 10%, but has only had limited effect on overall survival due to the constantly high (more than 30%) rate of distant metastasis.
However, it has been shown that complete eradication of the primary tumour observed in the histopathological specimen (pathological complete response, pCR) correlates with a favourable overall prognosis so obtaining a pCR might be beneficial. The aim of the study is to investigate whether the addition of bevacizumab to preoperative fluoropyrimidinebased chemoradiation improves pathological complete remission rate in locally advanced rectal cancer with acceptable toxicity. Secondary objectives are to evaluate pathological downstaging rate, histopathological R0 resection rate,sphincter preservation rate, perioperative surgical complication rate, local control, DFS, OS, late toxicity and quality of life.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
- radiotherapy: 45 Gy to the pelvis (25x 1.8 Gy on days 1-33, excluding weekends) plus 5.4 Gy on days 36-38 as a boost to the primary tumour (3 fractions of 1.8 Gy).Three- dimensional CT planing and a four field box technique with high energy photons (15 MV) will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.
- capecitabine 825 mg/m² p.o. twice daily on days 1-38 (including weekends),
- bevacizumab: at dose 5 mg/kg on days -14, 2, 16,30.
- Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation.
Postoperative treatment (in patients achieving histopathological R0 or R1 resection):capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks; 4 cycles (R0)or 6 cycles (R1) beginning 6-8 weeks after surgery
Type d'étude
Inscription (Anticipé)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Ljubljana, Slovénie, 1000
- Onstitute of Oncology, Zaloška 2
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male or female patients with histologically proven adenocarcinoma of the rectum (tumour located below the peritoneum), T3/4 or any node positive disease (clinical stage according the TNM classification system)
- No evidence of metastatic disease.
- The disease must be considered either resectable at the time of entry or thought to become resectable after preoperative chemoradiation.
- Age 18 - 80 years
- WHO Performance Status 0-2
- No prior radiotherapy, chemotherapy or any targeting therapy for rectal cancer
- Adequate hematological, hepatic and renal function Ability to swallow tablets
- Signed informed consent
- Patients must be willing and able to comply with the protocol for duration of the study
Exclusion Criteria:
- Malignancy of the rectum other than adenocarcinoma
- Any unrested synchronous colon cancer
- Other co-existing malignancy or malignancy within the past 5 years, with the exception of adequately treated in situ carcinoma of the cervix or basal cell carcinoma of the skin
- Significant heart disease (uncontrolled hypertension despite of medication (> 150/100 mmHg), NYHA class III or IV heart disease,unstable angina or myocardial infarction within the past 1 year prior the study entry, history of significant ventricular arrhythmia requiring treatment)
- Serious, non-healing wound, ulcer or bone fracture
- Evidence of active peptic ulcer or upper GI bleeding
- Evidence of bleeding diathesis or coagulopathy
- Chronic daily treatment with high-dose aspirin(>325mg/day)
- Current or recent (>10 days) use of full-dose of parenteral anticoagulants or thrombolytic agents for therapeutic purpose
- Patients receiving a concomitant treatment with drugs interacting with capecitabine such as flucitosine, phenytoin, or warfarin
- Known dihydropyrimidine dehydrogenase (DPD)deficiency
- Major surgery within 4 weeks prior to study treatment starts, or lack of complete recovery from the effects of major surgery or open biopsy
- Known hypersensitivity to biological drugs
- Treatment with any investigational drug within 30 days before beginning treatment with the study drug
- Pregnant or lactating patient
- Females with a positive or no pregnancy test unless childbearing potential can be otherwise excluded (amenorrheic for at least 2 years,hysterectomy or oophorectomy)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Pathological complete remission rate (pCR)
Délai: after pathological examination of surgical speciments
|
after pathological examination of surgical speciments
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Pathological response rate
Délai: Toxicity/safety:during preoperative treatment, early and late postoperative follow up
|
Toxicity/safety:during preoperative treatment, early and late postoperative follow up
|
Rate of sphincter sparing surgical procedure
Délai: Toxicity/safety:during preoperative treatment, early and late postoperative follow up
|
Toxicity/safety:during preoperative treatment, early and late postoperative follow up
|
Histopathological R0 resection rate
Délai: Toxicity/safety:during preoperative treatment, early and late postoperative follow up
|
Toxicity/safety:during preoperative treatment, early and late postoperative follow up
|
Acute and late toxicity
Délai: Toxicity/safety:during preoperative treatment, early and late postoperative follow up
|
Toxicity/safety:during preoperative treatment, early and late postoperative follow up
|
Loco-regional failure rate
Délai: Toxicity/safety:during preoperative treatment, early and late postoperative follow up
|
Toxicity/safety:during preoperative treatment, early and late postoperative follow up
|
Disease-free survival
Délai: Toxicity/safety:during preoperative treatment, early and late postoperative follow up
|
Toxicity/safety:during preoperative treatment, early and late postoperative follow up
|
Overall survival
Délai: Toxicity/safety:during preoperative treatment, early and late postoperative follow up
|
Toxicity/safety:during preoperative treatment, early and late postoperative follow up
|
Quality of life
Délai: Toxicity/safety:during preoperative treatment, early and late postoperative follow up
|
Toxicity/safety:during preoperative treatment, early and late postoperative follow up
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Vaneja Velenik, MD, PhD, Institute of Oncology, Ljubljana, Slovenia
Publications et liens utiles
Publications générales
- Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004 Oct 21;351(17):1731-40. doi: 10.1056/NEJMoa040694.
- Dunst J, Reese T, Sutter T, Zuhlke H, Hinke A, Kolling-Schlebusch K, Frings S. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol. 2002 Oct 1;20(19):3983-91. doi: 10.1200/JCO.2002.02.049.
- Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005 Nov 1;23(31):8136-9. doi: 10.1200/JCO.2005.02.5635. No abstract available.
- Camma C, Giunta M, Fiorica F, Pagliaro L, Craxi A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. JAMA. 2000 Aug 23-30;284(8):1008-15. doi: 10.1001/jama.284.8.1008.
- Velenik V, Anderluh F, Oblak I, Strojan P, Zakotnik B. Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial. Croat Med J. 2006 Oct;47(5):693-700.
- Duda DG, Jain RK, Willett CG. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol. 2007 Sep 10;25(26):4033-42. doi: 10.1200/JCO.2007.11.3985.
- Czito BG, Bendell JC, Willett CG, Morse MA, Blobe GC, Tyler DS, Thomas J, Ludwig KA, Mantyh CR, Ashton J, Yu D, Hurwitz HI. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):472-8. doi: 10.1016/j.ijrobp.2007.02.001.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système digestif
- Tumeurs
- Tumeurs par site
- Tumeurs gastro-intestinales
- Tumeurs du système digestif
- Maladies gastro-intestinales
- Maladies intestinales
- Tumeurs intestinales
- Maladies rectales
- Tumeurs colorectales
- Tumeurs rectales
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Antimétabolites, Antinéoplasique
- Antimétabolites
- Agents antinéoplasiques
- Agents antinéoplasiques immunologiques
- Inhibiteurs de l'angiogenèse
- Agents modulateurs de l'angiogenèse
- Substances de croissance
- Inhibiteurs de croissance
- Capécitabine
- Bévacizumab
Autres numéros d'identification d'étude
- ML21901
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur bevacizumab, capecitabine
-
Dana-Farber Cancer InstituteBristol-Myers Squibb; Genentech, Inc.Complété
-
Koen RoversHoffmann-La Roche; Comprehensive Cancer Centre The Netherlands; Dutch Cancer...RecrutementCancer colorectal | Tumeurs péritonéales | Tumeur colorectale | Carcinose péritonéale | Carcinome colorectal | Cancer péritonéal | Métastases péritonéales | Adénocarcinome colorectal | Tumeurs colorectales malignes | Tumeur péritonéale Carcinomatose secondaire maligne | Tumeur péritonéale maligne secondairePays-Bas, Belgique
-
National Cancer Institute (NCI)Actif, ne recrute pasCarcinome récurrent des trompes de Fallope | Carcinome ovarien récurrent | Carcinome péritonéal primitif récurrent | Cystadénocarcinome à cellules claires de l'ovaire | Adénocarcinome endométrioïde ovarien | Cystadénocarcinome séreux ovarien | Adénocarcinome à cellules claires de l'endomètre | Adénocarcinome... et d'autres conditionsÉtats-Unis
-
Harbin Medical UniversitySun Yat-sen University; Fudan University; Cancer Institute and Hospital, Chinese... et autres collaborateursInconnueTumeurs colorectales | ChimiothérapieChine
-
Hoffmann-La RocheComplétéGlioblastome multiformeSuisse, France, Royaume-Uni, Danemark
-
Spanish Cooperative Group for the Treatment of...Roche Pharma AGComplété
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.ComplétéCancer du col de l'utérus | Glioblastome | Cancer des ovaires | Cancer du poumon | Cancer rectalChine
-
Azienda Ospedaliero, Universitaria PisanaComplété
-
National Taiwan University HospitalRésilié
-
National Cancer Institute (NCI)Actif, ne recrute pasMélanome cutané de stade IV AJCC v6 et v7 | Mélanome cutané de stade IIIC AJCC v7 | Mélanome non résécableÉtats-Unis